Profile
Steffen Wagner is currently the Chief Executive Officer & Director at Advanz Pharma Corp.
Ltd.
He previously worked as the Executive Vice President-European Markets at STADA Arzneimittel AG.
Steffen Wagner active positions
Companies | Position | Start |
---|---|---|
ADVANZ PHARMA CORP. LIMITED | Chief Executive Officer | 2022-03-31 |
Former positions of Steffen Wagner
Companies | Position | End |
---|---|---|
STADA ARZNEIMITTEL | Corporate Officer/Principal | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
STADA Arzneimittel AG
STADA Arzneimittel AG Pharmaceuticals: OtherHealth Technology STADA Arzneimittel AG engages in the provision of healthcare and pharmaceutical products. It operates through the following segments: Generics, Consumer Healthcare, and Specialty. The Generics segment produces and distributes generic drugs. The Consumer Healthcare segment includes products such as OTC drugs, nutritional supplements and certain consumer healthcare products such as disinfectants and sunscreen. The Specialty segment includes branded generics, specialty generics, and biosimilars. Its brands include Zoflora, Grippostad, Nizoral, and Shampoo & Ladival. The company was founded on March 14, 1895 and is headquartered in Bad Vilbel, Germany. | Health Technology |
Advanz Pharma Corp. Ltd.
Advanz Pharma Corp. Ltd. Pharmaceuticals: MajorHealth Technology ADVANZ PHARMA Corp. Ltd. is a pharmaceutical company engages in the provision of branded and unbranded products. The firm specializes in anti-Infectives and endocrinology therapy areas. It operates through the following segments: Advanz Pharma International; Advanz Pharma North America; and Corporate. The Advanz Pharma International segment include portfolio of branded and generic products that are sold to wholesalers, hospitals, and pharmacies. The Advanz Pharma North America segment comprises branded products and authorized generic contracts that focuses primarily on the U.S. pharmaceutical market. The Corporate segment represents the centralized costs. The company was founded by Mark L. Thompson on January 20, 2010 and is headquartered in St. Helier, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Steffen Wagner